Introduction {#s1}
============

With emerging antimicrobial resistance posing a serious threat to global public health, promoting judicious use of antibiotics has become a top priority for governments worldwide. As a consequence, clinical practice guidelines for common infectious diseases, including acute otitis media (AOM), have been introduced and updated in many countries over the past decades.[@R1] Although AOM guidelines vary regarding specific recommendations across countries, they generally emphasise the importance of accurate diagnosis and adequate analgesia as well as advocating selective antibiotic prescribing.[@R1]

It has been suggested that guideline adherence for AOM may be suboptimal[@R2] due to a variety of factors, such as fear of serious complications and parental pressure to prescribe antibiotics.[@R3] In daily practice, antibiotics are commonly prescribed to children with AOM, ranging from around 50% in the Netherlands[@R4] to 80% in the USA,[@R5] whereas analgesics are only recommended in a minority of cases.[@R6]

However, the true impact of introducing AOM guidelines on prescription of antibiotics and analgesics for children with AOM in daily practice has not been reviewed systematically. We aim to do so and provide an overview of current available studies that compare prescription data before and after national AOM clinical practice guideline introduction.

Methods {#s2}
=======

Search strategy and study selection {#s2a}
-----------------------------------

We performed systematic searches of the PubMed, Embase and Cochrane Library databases from inception to 6 June 2017 using database-specific syntaxes of keywords relevant to 'acute otitis media' and 'guidelines' (see online [supplementary](#SP1){ref-type="supplementary-material"} for full search strategies). After removing duplicates (RefWorks), two reviewers (YD and RTvU) independently screened titles and abstracts for inclusion. Discussion with a third and fourth reviewer (MLAdH and RPV) resolved any discrepancies. We screened reference lists of included studies for additional studies.
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We included all original studies, irrespective of design, setting or language, evaluating the effects of the introduction of national clinical practice guidelines on prescription of antibiotics (rate and type) and/or analgesics for children (up to the age of 16 years) with AOM by comparing data before and after guideline introduction. We only included studies in which the time between data collection before and after guideline introduction was less than 5 years; this was to minimise the impact of other factors that may affect AOM epidemiology and subsequent prescription rates, for example, the introduction of pneumococcal conjugate vaccines and anti-smoking campaigns.

Data extraction and synthesis {#s2b}
-----------------------------

The primary outcome of interest was the overall antibiotic prescription rate for AOM. Secondary outcomes included type of antibiotic prescribed and analgesic prescription rate.

Two review authors (YD and RTvU) independently extracted the following data from the included studies: characteristics of study (year, country, design, setting and data source), study population (number and age of children with AOM), guideline details (date of introduction, method of dissemination and management recommendations) and data on our predefined outcomes. Discussion with a third and fourth reviewer (MLAdH and RPV) resolved any discrepancies. To obtain further information on guideline dissemination strategies, we contacted authors of the original publications as well as clinical scientists involved in guideline development in countries subject to this review.

Methodological quality of the included studies was assessed by three reviewers independently (YD, RTvU and RPV) using 'The Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool',[@R7] and any discrepancies were resolved by discussion.

Antibiotic prescription rates, type of antibiotic and analgesic prescription rates before and after introduction of the AOM clinical practice guideline were presented for each study individually. Where before and after guideline introduction data were reported for individual years or subgroups, (such as age), we aimed to calculate averages.

Results {#s3}
=======

Search results and study characteristics {#s3a}
----------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the search results; 20 of the 411 unique records were considered potentially relevant. Of these, seven studies[@R8] were suitable for inclusion in this review. For detailed information of the included studies (see [table 1](#T1){ref-type="table"}); the seven studies were conducted in six countries: France, Italy, Spain, Sweden, UK and USA (two studies). All were observational studies using longitudinal data of children aged under 15 years; they differed substantially in terms of setting (primary vs secondary care), number of patients (n=200--4.6 million), study duration (6 months--10 years longitudinal data) and data source (routine care, insurance databases or electronic surveys).
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###### 

Baseline characteristics of included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                  Country   Study design    Participants    Data source   Time        Outcomes reported                                                  
  ------------------------- --------- --------------- --------------- ------------- ----------- --------------------- ------- ------------------------------------ ------------------------------------------------
  Tyrstrup *et al* [@R14]   Sweden    Observational   N=1 245 599\*   PC            1--12 Y     Routine care          2010    Pre: 2008\                           Antibiotic prescription rate\
                                                                                                                              Post: 2013                           Type of antibiotic

  Palma *et al* [@R11]      Italy     Observational   N=4559\         SC            0--14 Y     Routine care          2010    Pre: 2007--2010\                     Antibiotic prescription rate\
                                                      N~pre~=2692\                                                            Post: 2011--2013                     Type of antibiotic
                                                      N~post~=1867                                                                                                 

  Levy *et al* [@R9]        France    Observational   N=14 661        SC            6 M--2 Y    Routine care          2011    Pre1: November 2009--October 2010\   Type of antibiotic
                                                                                                                              Pre2: November 2010--October 2011\   
                                                                                                                              Post: November 2011--October 2012    

  McGrath *et al* [@R10]    USA       Observational   N=4 629 460     SC            3 M--12 Y   Insurance databases   2004    Pre: 2000--2003\                     Antibiotic prescription rate
                                                                                                                              Post1: 2005--2007\                   
                                                                                                                              Post2: 2008--2011                    

  Coco *et al* [@R8]        USA       Observational   N=1114\         PC+SC         6 M--12 Y   Electronic surveys    2004    Pre: January 2002--June 2004\        Antibiotic prescription rate\
                                                      N~pre~=584\                                                             Post: July 2004--December 2006       Type of antibiotic Analgesic prescription rate
                                                      N~post~=530                                                                                                  

  Thompson *et al* [@R13]   UK        Observational   N=464 845†      PC            3 M--15 Y   Routine care          2003\   Pre: 1999--2001\                     Antibiotic prescription rate
                                                                                                                      2004    Post: 2005--2006                     

  Ríos *et al* [@R12]       Spain     Observational   N=200\          PC            2--15 Y     Routine care          2001    Pre: January--March 2000\            Type of antibiotic
                                                      N~pre~=102\                                                             Post: January--March 2002            
                                                      N~post~=98                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Number of patient years.

†Number included in total study period of 17 consecutive years, no specific information on number of children over 1999--2001 and 2005--2006 periods.

M, months; N, number of patients; N/A, not available; PC, primary care setting; SC, secondary care setting; Y, years.

[Table 2](#T2){ref-type="table"} summarises the key guideline recommendations of the included studies. Detailed information on guideline dissemination strategies was obtained for Italy, Sweden, UK and USA ([table 3](#T3){ref-type="table"}). The method of dissemination varied considerably across countries, ranging from passive dissemination through online publication or paper copies targeted at individual physicians only to extensive (public) media attention, interactive workshops and joint antibiotic stewardship campaigns.

###### 

Guideline recommendations in included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                  Country                                                                                          Year                                                          Condition                                                                                Guideline recommendation (summary)   
  ------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------ -----------------------------------------------------------------
  Tyrstrup *et al* [@R14]   Sweden                                                                                           2010                                                          Children 1--12 years with uncomplicated AOM                                              First line                           Wait-and-see for 3 days

  Second line               Penicillin V (first choice antibiotic)                                                                                                                                                                                                                                                       

  Palma *et al* [@R11]      Italy                                                                                            2010                                                          Children \>2 years with uncomplicated,\                                                  First line                           Analgesics, wait-and-see for 3 days
                                                                                                                                                                                           non-severe AOM                                                                                                                

  Second line               First choice: high-dose amoxicillin (80--90 mg per kg per day)\                                                                                                                                                                                                                              
                            Second choice: cephalosporin                                                                                                                                                                                                                                                                 

                                                                                                                                                                                           Children 6 months--2 years with uncomplicated AOM Children \>2 years with severe AOM\*   First line                           First choice: high-dose amoxicillin (80--90 mg per kg per day)\
                                                                                                                                                                                                                                                                                                                         Second choice: cephalosporin

  Levy *et al* [@R9]        France                                                                                           2011                                                          Children \>2 years with uncomplicated AOM                                                First line                           Wait-and-see, reassessment after 48--72 hours

  Second line               High-dose amoxicillin (80--90 mg per kg per day)                                                                                                                                                                                                                                             

                                                                                                                                                                                           Children \<2 years with uncomplicated AOM\                                               First line                           High-dose amoxicillin (80--90 mg per kg per day)
                                                                                                                                                                                           Children \>2 years with severe AOM\*                                                                                          

  Second line               Amoxicillin/clavulanic-acid or cefpodoxime in case of treatment failure                                                                                                                                                                                                                      

  McGrath *et al* [@R10]    USA                                                                                              2004                                                          Children \>2 years with uncomplicated,\                                                  First line                           Analgesics, wait-and-see for 3 days
                                                                                                                                                                                           non-severe AOM                                                                                                                

  Second line               First choice: high-dose amoxicillin (80--90 mg per kg per day)\                                                                                                                                                                                                                              
                            Second choice: cephalosporin                                                                                                                                                                                                                                                                 

                                                                                                                                                                                           Children 6 months--2 years with uncomplicated AOM Children \>2 years with severe AOM\*   First line                           First choice: high-dose amoxicillin (80--90 mg per kg per day)\
                                                                                                                                                                                                                                                                                                                         Second choice: cephalosporin

  Coco *et al* [@R8]        USA                                                                                              2004                                                          Children \>2 years with uncomplicated,\                                                  First line                           Analgesics, wait-and-see for 3 days
                                                                                                                                                                                           non-severe AOM                                                                                                                

  Second line               First choice: high-dose amoxicillin (80--90 mg per kg per day)\                                                                                                                                                                                                                              
                            Second choice: cephalosporin                                                                                                                                                                                                                                                                 

                                                                                                                                                                                           Children 6 months--2 years with uncomplicated AOM Children \>2 years with severe AOM\*   First line                           First choice: high-dose amoxicillin (80--90 mg per kg per day)\
                                                                                                                                                                                                                                                                                                                         Second choice: cephalosporin

  Thompson *et al* [@R13]   UK                                                                                               2003\                                                         Children \>2 years with uncomplicated,\                                                  First line                           Analgesics, wait-and-see for 24--72 hours
                                                                                                                             2004                                                          non-severe AOM                                                                                                                

                            Second line                                                                                      Amoxicillin thrice daily 125--250 mg, for 5 days\                                                                                                                                           
                                                                                                                             Second choice: erythromycin, azithromycin or clarithromycin                                                                                                                                 

                                                                                                                                                                                           Children \<2 years or severe AOM or recurrent infections                                 First line                           Amoxicillin thrice daily 125--250 mg, for 5 days

  Rios, *et al* [@R12]      Spain                                                                                            2001                                                          Children \>6 months with uncomplicated AOM                                               First line                           High-dose amoxicillin for a minimum of 5 days

  Second line               Amoxicillin/clavulanic-acid or ceftriaxone if no response within 48--72 hours                                                                                                                                                                                                                

                                                                                                                                                                                           Children \<6 months with uncomplicated AOM\                                              First line                           Amoxicillin/clavulanic-acid or ceftriaxone
                                                                                                                                                                                           Children \>6 months with severe AOM                                                                                           

  Second line               Tympanocentesis and treatment according to results of Gram staining and antibiotic sensitivity                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Severe AOM is defined as moderate to severe otalgia with fever \>39°C.

AOM, acute otitis media; N/A, not available.

###### 

Guideline dissemination efforts in included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                  Country   Year    Online publication   Online self-care advice to the public   Hard copy dissemination   Public media campaigns   Newspapers   Workshops or lectures for physicians   Debates or round tables for physicians   Antibiotic stewardship campaigns[\*](#tblfn6){ref-type="fn"}   Patient leaflet
  ------------------------- --------- ------- -------------------- --------------------------------------- ------------------------- ------------------------ ------------ -------------------------------------- ---------------------------------------- -------------------------------------------------------------- -----------------
  Tyrstrup *et al* [@R14]   Sweden    2010    ✓                    ✓                                                                 ✓                        ✓            ✓                                      ✓                                        ✓                                                              ✓

  Palma *et al* [@R11]      Italy     2010    ✓                                                            ✓                                                               ✓                                      ✓                                                                                                       

  Levy *et al* [@R9]†       France    2011    ✓                                                                                                                                                                                                                                                                           

  McGrath *et al* [@R10]    USA       2004    ✓                    ✓                                                                                          ✓                                                                                                                                                           

  Coco *et al* [@R8]        USA       2004    ✓                    ✓                                                                                          ✓                                                                                                                                                           

  Thompson *et al* [@R13]   UK        2003\   ✓                                                            ✓                                                                                                                                                                                                              
                                      2004                                                                                                                                                                                                                                                                                

  Ríos *et al* [@R12]†      Spain     2001    ✓                                                                                                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Antibiotic stewardship campaigns specifically set up with the aim to promote guideline awareness, through various methods (eg, lectures, educational outreach visits).

†Guideline dissemination methods solely based on article, authors not available for correspondence.

Risk of bias assessment and study findings {#s3b}
------------------------------------------

Risk of bias was judged serious in six studies and critical in one; see [figure 2](#F2){ref-type="fig"}. The primary and secondary outcome data are illustrated in [figures 3 and 4](#F3 F4){ref-type="fig"}. Two of the five studies reporting antibiotic prescription rates before and after guideline introduction showed no or a negligible effect. Three studies showed a decline of 5%--12% up to 3 years after guideline introduction.
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One US study reported both the short- and long-term impact of guideline introduction; the decline of 9% in the first 3 years decreased to 5% after four to 6 years.

In four out of five studies reporting on the type of antibiotic prescribed, prescription of the recommended first choice antibiotic, either amoxicillin or penicillin V, increased by 9%--58% after guideline introduction, with inverse trends for amoxicillin/clavulanic acid which decreased by 7%--36%.

Only one US study reported on analgesic prescription rates; this increased from 14% before to 24% after guideline introduction.

Discussion {#s4}
==========

The introduction of national AOM clinical practice guidelines seems to have at best a modest impact on antibiotic and analgesic prescribing; antibiotic prescription rates decrease by a maximum of 12% and analgesic rates increase by 10%. Its effect on the type of antibiotic is more substantial with an increase of up to 58% for the recommended first choice antibiotic.

In line with available literature,[@R15] results from the study of Tyrstrup *et al* [@R14] suggest that tailored guideline dissemination may have a larger impact on antibiotic prescription rates than passive dissemination only. Our findings also indicate that physicians find it easier to substitute rather than refrain from antibiotic prescribing. Reasons include their concerns about the risk of the child falling seriously ill when not prescribing antibiotics, or missing a diagnosis which would have been adequately treated with antibiotics.[@R17] This is especially the case when dealing with young children, or in consultations in which physicians perceive parental pressure to prescribe antibiotics.[@R17] Apparently, many physicians are either not convinced of, or unfamiliar with, the literature that refutes the risks of restrictive prescribing[@R18] and parental expectations of antibiotics.[@R3]

Our findings should be interpreted with some caution. Despite our efforts to minimise the impact of external factors affecting childhood AOM epidemiology and prescribing patterns, such as anti-smoking campaigns, pneumococcal conjugate vaccination and strategies to promote breast-feeding,[@R20] we cannot rule out this has influenced our results. Also, we were not able to account for ongoing prescribing trends prior to the introduction of the guideline; none of the studies applied interrupted time-series analysis.[@R22] Importantly, dissemination of the guideline to the general audience suggesting that parents can manage milder cases of AOM themselves can lead to fewer overall AOM consultations and subsequent antibiotic prescriptions.[@R23] Nevertheless, only two out of the seven studies reported on annual fluctuations in AOM consultation rates and none of them accounted for this in their analyses.[@R13] Besides, when parents do self-manage these milder cases of AOM, physicians may be faced with more severe AOM and thus prescribe antibiotics more frequently (leading to a relative increase over time). These aforementioned trends are not captured in the studies. Neither are the phenomena that, with explicit diagnostic guidance, physicians may diagnose AOM more accurately, leading to fewer overall diagnoses and antibiotic prescriptions, but at the same time a higher prescription rate per diagnosis.

Finally, the vast majority of analgesics for AOM are obtained over-the-counter rather than prescribed. This implies that our results regarding analgesic prescriptions for AOM are incomplete and preclude strong conclusions.

Conclusion {#s5}
==========

Based on what is published, the introduction of national AOM clinical practice guidelines seems to have at best a modest impact on antibiotics and analgesics prescription rates for childhood AOM. Future studies evaluating the impact of clinical guidelines using longitudinal observational data should use a quasi-experimental approach, and take fluctuations in AOM consultation rates into account, to provide more meaningful estimates on the impact on antibiotic and analgesic prescribing.
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